TG Therapeutics, Inc.

Biotech

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 1 drug with upcoming expirations

Activity

Recent Activity

Last 14 days

Jul 9, 2026

Recruiting

Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS)

Jul 8, 2026

Recruiting

A Phase 2, Multicenter, Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector Device Versus Syringe in Patients With Multiple Sclerosis

Earlier

Jun 30, 2026TrialA Phase 2, Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Treatment Following Induction With Efgartigimod Administration in Adults With Myasthenia Gravis

Jul 9, 2025TrialA Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)

May 6, 2025TrialA Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders

Jun 13, 2023TrialStudy to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab

Dec 28, 2022FDABRIUMVI — BRIUMVI

Apr 28, 2021TrialStudy of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia

3 more events

Feb 5, 2021FDAUkoniq — UKONIQ

Nov 18, 2019TrialAn Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis

Aug 5, 2019TrialStudy to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

2 patent groups across drugs · Source: FDA Orange Book

DrugExpires

Ukoniq5 patentsJul 2, 2033 Ukoniq3 patentsMay 26, 2035

Regulatory

Regulatory Timeline

20211 event

FDAFeb 5

Ukoniq — UKONIQ

Application NDA213176 (NDA)

20221 event

FDADec 28

BRIUMVI — BRIUMVI

Application BLA761238 (BLA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)